Methods for treating gastro-esophageal reflux disease and emesis with optically pure (-) cisapride
US5618828A · kind A · utility
10Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 1993 |
| Grant date | Apr 8, 1997 |
| Priority date | — |
| Expiry date | Oct 12, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed utilizing the optically pure (-) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.